NovaBridge Biosciences
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology. The company operates through a network of subsidiaries in the United States, China, Hong Kong, Switzerland, and the Cayman Islands to advance product candidates and support business development, clinical development, and portfolio management.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDrug candidates for cancer indications, including CLDN18.2-targeted programs and related assets.
Development-stage medicines targeting eye diseases, including the VIS-101 program.
Out-licensing, strategic collaborations, and other transactions around pipeline assets.
Internal discovery, clinical development, and management of the therapeutic portfolio.
Asiakkaat
NovaBridge does not sell large commercial product volumes; its primary counterparties are pharmaceutical and biotech partners, clinical investigators, and future healthcare customers for its pipeline assets. Value is created by advancing assets such as givastomig and VIS-101 to the point where they can be licensed, co-developed, or commercialized. End demand ultimately comes from patients and physicians in oncology and ophthalmology, but the near-term economic buyers are strategic partners and collaborators.
Buy or license development-stage assets, or co-develop programs to share risk and access pipeline opportunities.
Clinical sites, investigators, CROs, and trial vendors that enable execution of oncology and ophthalmology studies.
The eventual end users of approved therapies in gastric cancer, other CLDN18.2-positive tumors, and ophthalmic disease.
Equity investors who fund the company in anticipation of pipeline progress and partnering value.
Strategia
NovaBridge's strategy is to identify differentiated therapeutic opportunities, generate clinical evidence, and choose the most value-efficient path for each asset. The company emphasizes partnering, licensing, or direct commercialization depending on the program, with a portfolio led by givastomig and VIS-101. This approach is designed to build value through focused development rather than broad internal commercialization.
Clinical data is the main value driver for a bispecific oncology asset and determines partnering interest.
A second lead program broadens the pipeline and creates a separate value stream beyond oncology.
Partnerships can fund development and convert pipeline value without requiring full commercial infrastructure.
Maantiede
NovaBridge is organized as a global biotech group with operating and holding entities across the United States, mainland China, Hong Kong, Switzerland, the Cayman Islands, and the British Virgin Islands. Development activity spans the U.S. and China, while the corporate structure also supports intellectual property holding and investment-holding functions across multiple jurisdictions. This geography matters because clinical execution, asset ownership, and partnering can be split across countries and legal entities.
Riskit
The business depends on successful clinical development, so setbacks in efficacy, safety, or trial execution can materially reduce asset value. As a development-stage biotech with cross-border entities, NovaBridge also faces financing, partnering, regulatory, and intellectual-property risks that are typical for the sector. Clinical-stage companies can experience large swings in value from a single data readout or transaction outcome.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Pipeline value depends on favorable efficacy and safety results in human trials.
Kohdistuu - Partnering and financing dependenceVaikutus: KorkeaTodennäköisyys: Korkea
The model relies on collaborations, licensing, and external capital to fund development.
Kohdistuu: Business development and portfolio strategy
- Regulatory approval uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biotech assets must clear extensive review before commercialization.
Kohdistuu: Oncology and ophthalmology programs
- Intellectual property riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Value creation in biotech depends on protected composition, method, and platform rights.
Kohdistuu: CLDN18.2 and ophthalmology assets
Kirjanpito
Harkinnanvaraiset erätEmployee awards materially increased administrative expenses in the period shown.
Vaikutus: Affects operating expenses and reported loss
Disposal gains and unrealized valuation changes can flow through other income.
Vaikutus: Can create volatility in non-operating results
R&D and trial-related costs are typically expensed as incurred, making results highly sensitive to program timing.
Vaikutus: Drives period-to-period operating loss
The company consolidates entities in multiple jurisdictions, creating translation effects in equity and comprehensive income.
Vaikutus: Affects consolidated balance sheet and equity
Operating lease disclosures show cash lease payments and related obligations that affect liabilities and cash flow.
Vaikutus: Affects operating cash flow and lease liabilities
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Nuvation Bio Inc.
NUVB · Pharmaceutical Preparations
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Nuvalent, Inc.
Pharmaceutical Preparations
Adlai Nortye Group Ltd.
ANL · Pharmaceutical Preparations
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
Päivitetty: 28.9.2026